A malaria vaccine has shown promising results in early stage clinical trials, a study suggests.
Researchers found the vaccine, which is being developed in the US, protected 12 out of 15 patients from the disease, when given in high doses.
The method is unusual because it involves injecting live but weakened malaria-causing parasites directly into patients to trigger immunity.
The research is published in the journal Science.
Lead author Dr Robert Seder, from the Vaccine Research Center at the National Institutes of Health, in Maryland, said: “We were excited and thrilled by the result, but it is important that we repeat it, extend it and do it in larger numbers.”
It has been known for several decades that exposure to mosquitoes treated with radiation can protect against malaria.
However, studies have shown that it takes more than 1,000 bites from the insects over time to build up a high level of immunity, making it an impractical method of widespread protection.
Instead, a US biotech company called Sanaria has taken lab-grown mosquitoes, irradiated them and then extracted the malaria-causing parasite (Plasmodium falciparum), all under the sterile conditions.
They are clearly very early stage trials in small numbers of volunteers, but without question we are extremely encouraged by the results”
Dr Ashley BirkettPath Malaria Vaccine Initiative
These living but weakened parasites are then counted and placed in vials, where they can then be injected directly into a patient’s bloodstream. This vaccine candidate is called PfSPZ.
To carry out the Phase-1 clinical trial, the researchers looked at a group of 57 volunteers, none of whom had had malaria before.
Of these, 40 received different doses of the vaccine, while 17 did not. They were then all exposed to the malaria-carrying mosquitoes.
The researchers found that for the participants not given any vaccine, and those given low doses, almost all became infected with malaria.
However for the small group given the highest dosage, only three of the 15 patients became infected after exposure to malaria.
Dr Robert Seder said: “Based on the history, we knew dose was important because you needed 1,000 mosquito bites to get protection – this validates that.
“It allows us in future studies to increase the dose and alter the schedule of the vaccine to further optimise it. The next critical questions will be whether the vaccine is durable over a long period of time and can the vaccine protect against other strains of malaria.”
The Latest on: Malaria vaccine
- Placental malaria vaccine candidate antigen VAR2CSA displays atypical domain architecture in some Plasmodium falciparum strainson December 6, 2019 at 2:23 am
In malaria-endemic areas, pregnant women commonly suffer from placental malaria (PM ... Several lines of evidence support VAR2CSA as the leading vaccine candidate to prevent PM: parasites isolated ...
- The Gavi coalition boosts the global stockpile of Ebola vaccineson December 5, 2019 at 8:03 am
On a different matter, the Gavi board also agreed to continue support for three pilot projects currently underway in Kenya, Mali and Ghana to see if the world’s first malaria vaccine, RTS,S, is ...
- Gavi Board approves new Ebola vaccine programmeon December 5, 2019 at 6:46 am
Vaccine Alliance will fund a global stockpile of Ebola vaccines and extend support for malaria vaccine pilots New Delhi, 5 December 2019 – A global emergency stockpile of Ebola vaccines will be ...
- WHO urges focus on pregnant women, children to wipe out malariaon December 4, 2019 at 9:03 am
However, it highlighted that three countries—Ghana, Kenya and Malawi—are engaged in clinical trials on the malaria vaccine, which, the report said, had been shown to reduce four in ten malaria cases ...
- Global report shows again that progress against malaria has slowedon December 4, 2019 at 5:59 am
If these measures prove effective, WHO will formulate new policy recommendations. Another key component in the fight against malaria would be a vaccine. In 2019, three African countries introduced the ...
- Malaria killed 405,000 in 2018 as medical funding stalled: WHOon December 3, 2019 at 8:42 pm
In November, Science Magazine reported that the first malaria vaccine was rolled out in Malawi, Ghana and Kenya. Meanwhile, it was reported last November that a United Nations peacekeeper from China ...
- Number of cases of malaria still at 'unacceptably high' levelson December 3, 2019 at 4:06 pm
including the introduction of the first ever malaria vaccine in three countries this year, the successful funding round of the Global Fund to Fight Aids, Malaria and Tuberculosis and the launch of ...
- African farmers use drones to fight deadly malaria-carrying mosquitoeson November 30, 2019 at 6:00 pm
Tanzania has the third largest population at risk of malaria in all of Africa. The global effort to eliminate malaria is ongoing, with Malawi becoming the first nation to pilot a vaccine for children.
- Dengue fever vaccine almost outon November 29, 2019 at 1:44 am
Colombia and Brazil received the vaccine during the trials. The disease is caused by four types of the Dengue virus, which is transmitted to humans by Aedes aegypti and Aedes albopictus mosquitoes ...
- Attractive Market Opportunities in the Live Vaccines Market by 2029on November 28, 2019 at 11:53 pm
Download the sample copy of Report with table of contents and Figures @https://www.futuremarketinsights.com/reports/sample/rep-gb-10252 Live vaccines s Market: Drivers and Restraints Increasing ...
via Google News and Bing News